IGM Biosciences, Inc. [NASDAQ: IGMS] has reported the clinical data from the Phase I study of IGM-2323 at the 62nd American Society of Hematology (ASH) Annual Meeting. The corporation has carried out the study to assess the IGM-2323 in patients suffering from relapsed/refractory B cell non-Hodgkin’s lymphoma (NHL).
IGM Biosciences has shared that the study has shown the encouraging result as 14 out of 16 sufferers enrolled in the trial have undergone the reduction in tumor size which is the greatest achievement for the company. Those Registered patients were treated with an increase in the dose of IGM-2323. It has been disclosed that the firm will continue the dose rise in further studies and expected that the dose for Phase II will be in the range of between 100 and 1000 mg.
IGM Biosciences has revealed that none of the patients have shown the negative impact of the IGM-2323 doses and no neurotoxicity has been noticed in the sufferers. IMG-2323 can limit the stimulation of T-cells. Biosciences is planning to use this T cell engager technology to further hematologic & solid tumor objectives and signs.
The first-in-human clinical trial has shown the expected result. The biotechnology firm is planning to continue the advancement of IGM-8444, IGM-2323, & its vast pipeline of IgM antibodies. Furthermore, IGM Biosciences is scheduled to share the pre-clinical data from IGM-8444 on Dec 6, 2020. Presently, the firm is registering sufferers in the Phase I trial of IGM-8444 alone and in conjunction with the chemo-based treatments of solid tumors.
Shares of IGM Biosciences soared 2.66% as it gained +1.62 during the trading session of Friday. In the past 52-weeks of trading, the company’s share fluctuated between the low range of $19.95 and a high range of $89.81. It has surged 213.58% from its 52-weeks low and plunged -30.34% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 13.90. This company’s market capitalization has remained high, hitting $1.87 billion at the time of writing.